Description:

NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients) A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B00492A-70E3-51F1-E044-0003BA3F9857

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B00492A-70E3-51F1-E044-0003BA3F9857
Keywords:
  1. 12/18/14 12/18/14 - Martin Dugas
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 6/16/15 6/16/15 -
Uploaded on:

January 9, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00408408 Treatment - NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients) - 2506570v1.0

No Instruction available.

  1. StudyEvent: NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients)
    1. No Instruction available.
Header
Unnamed2
Are data amended
Unnamed3
Total Number of Cycles Given (Docetaxel/Gemcitabine)
Why did treatment end or not begin (Docetaxel/Gemcitabine)
Unnamed4

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial